Asian Pacific Journal of Cancer Prevention

  • 제17권12호
  • /
  • Pages.5179-5183
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Value of Prepro-Gastrin Releasing Peptide in Lung Cancer Patients; NCI-Prospective Study

  • Shafik, Nevine F (Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University) ;
  • Rahoma, M (Surgical Oncology Department, National Cancer Institute, Cairo University) ;
  • Elshimy, Reham AA (Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University) ;
  • El kasem, Fatma M Abou (Medical Oncology Department National Cancer Institute, Cairo University)
  • 발행 : 2016.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Prior series investigated the expression of prepro-gastrin releasing peptide (prepro-GRP) in the peripheral blood of lung cancer patients. Our aim was to assess any prepro-GRP role as a prognostic factor for small cell lung cancer (SCLC) and NSCLC and correlations with clinical presentation and treatment outcome. Methods: A prospective study was conducted during the time period from the beginning of January 2012 till the end of January 2014. Prepro-GRP expression was analysed using a nested RT-PCR assay in peripheral blood of 62 untreated lung cancer patients attending the National Cancer Institute (NCI), Cairo University, and 30 age and sex matched healthy volunteers. Results: Among the 62 lung cancer cases, there were 24 (38.7%) SCLC, and 38 (61.3%) NSCLC (10 squamous cell carcinomas, 12 adenocarcinomas, 11 large cell carcinomas, 4 undifferentiated carcinomas, and 1 adenosquamous carcinoma). Twenty six patients (41.9%) were prepro-GRP positive. Prepro-GRP expression was higher (58.3%) among SCLC patients compared to NSCLC (squamous cell carcinoma (15.4%), large cell carcinoma (36.4%), and adenocarcinoma (25%)). Mean OS among prepro-GRP negative cases was longer than that among preprogastrin positive cases (17.6 vs 14.9 months). The mean PFS durations among preprogastrin negative versus positive cases were 7.7 vs 4.6 months (p= 0.041). No difference in response to chemotherapy was identified between the groups (p=0.983). Conclusion: Prepro-GRP is suggested to be a useful prognostic marker for lung cancer patients, especially with the fast- growing, bad prognostic SCLC type. More studies should aim at detailed understanding of the mechanisms of prepro-GRP action and its use in monitoring the response to treatment in a larger cohort.

키워드

참고문헌

  1. American Cancer Society (2016). Cancer facts and figures 2016. Atlanta:American cancer society. available: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf.
  2. Beasley MB, Brambilla E, Travis WD (2005). The 2004 world health organization classification of lung tumors. Semin Roentgenol, 40, 90-7. https://doi.org/10.1053/j.ro.2005.01.001
  3. Cascone T, Gold KA, Glisson BS (2016). Small cell carcinoma of the Lung. Kantarjian H, Wolff R, eds. The MD Anderson Manual of Medical Oncology. 3rd ed. New York, NY: McGraw-Hill Education, pp 323-42.
  4. Chen CL, Hsu LI, Chiou HY, et al (2004). Ingested arsenic, cigarette smoking, and lung cancer risk: A follow-up study in arseniasis-endemic areas in Taiwan. JAMA, 292, 2984-90. https://doi.org/10.1001/jama.292.24.2984
  5. Cuttitta F, Carney DN, Mulshine J, et al (1985). Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature, 316, 823-6. https://doi.org/10.1038/316823a0
  6. De Martel C, Ferlay J, Franceschi S, et al (2012). Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol, 13, 607-15. https://doi.org/10.1016/S1470-2045(12)70137-7
  7. Edge Stephen B, Carolyn CC (2010). The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17.6, 1471-4. https://doi.org/10.1245/s10434-010-0985-4
  8. Fruh M, De Ruysscher D, Popat S, et al (2013). Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24, 99-105.
  9. Ibrahim AS, Khaled HM, Mikhail NN, et al (2014). Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J Cancer Epidemiolo, 437971.
  10. Lacroix J, Becker HD, Woerner SN, et al (2001). Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by prepro GRP-specific RT-PCR. Int J Cancer, 92, 1-8. https://doi.org/10.1002/1097-0215(200102)9999:9999<::AID-IJC1159>3.0.CO;2-5
  11. Liu L, Liao G, He P, et al (2008). Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun, 372, 756-60. https://doi.org/10.1016/j.bbrc.2008.05.101
  12. Markowitz SB, Levin SM, Miller A, et al (2013). Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American Insulator Cohort. Am J Respir Crit Care Med, 188, 90-6. https://doi.org/10.1164/rccm.201302-0257OC
  13. Mauri D, Pentheroudakis G, Bafaloukos D, et al (2006). Nonsmall cell lung cancer in the young: Aretrospective analysis of diagnosis, management and outcome data. Anticancer Res, 26, 3175-81.
  14. Miyake Y, Kodama T, Yamaguchi K (1994). Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res, 54, 2136-40.
  15. Moody TW (1998). Growth factors and receptors in small cell lung cancer. In: Kane MA, Bunn PJ. Biology of lung cancer. Lung biology in health and disease, vol. 122. New York: Marcel Dekker, pp 337-70.
  16. Pietanza MC, Krug LM, Wu AJ, et al (2015). Small cell and neuroendocrine tumors of the lung. DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia, Pa: Wolters Kluwer Health, 536-59.
  17. Planchard D, Le Pechoux C (2011). Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer, 47, 272-83.
  18. Prizment AE, Yatsuya H, Lutsey PL, et al. (2014) Smoking behavior and lung cancer in a biracial cohort: The atherosclerosis risk in communities study. Am J Prev Med, 4, 624-32.
  19. Rahouma M, Galal G, Kamel M, et al (2015) Bilobectomy for lung cancer: postoperative results, and long-term outcomes. J Thorac Oncol, 10, 444-5.
  20. Ramalingam S, Pawlish K, Gadgeel S, et al (1998). Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database. J Clin Oncol, 16, 651-7. https://doi.org/10.1200/JCO.1998.16.2.651
  21. Russel PJ, O'Mara SM, Raghavan D (1990). Ectopic hormone production by small cell undifferentiated carcinomas. Mol Cell Endcrinol, 71, 1-12. https://doi.org/10.1016/0303-7207(90)90068-J
  22. Salto T, Kobayashi M, Harada R, et al (2003). Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA. Cancer, 97, 2504-11. https://doi.org/10.1002/cncr.11378
  23. Schmid K, Kuwert T, Drexler H (2010). Radon in indoor spaces: an underestimated risk factor for lung cancer in environmental medicine. Dtsch Arztebl Int, 107, 181-6.
  24. Sher T, Dy GK, Adjei AA (2008). Small cell lung cancer. Mayo Clin Proc, 83, 355-67. https://doi.org/10.4065/83.3.355
  25. Shingyoji M, Takiguchi Y, Watanabe R, et al (2003). Detection of tumor specific gene expression in bone marrow and peripheral blood from patients with small cell lung carcinoma. Cancer, 97, 1057-62. https://doi.org/10.1002/cncr.11108
  26. Shokral la HA, Rahouma M (2015) . Prognostic clinico-pathological features of 99 cases advanced non-small cell lung cancer-egyptian national cancer institute. Advances in Lung Cancer, 4, 29-36. https://doi.org/10.4236/alc.2015.43005
  27. Spindel ER, Chin WW, Price J, et al (1984). Cloning and characterization of cDNAs encoding human gastrinreleasing peptide. Proc Natl Acad Sci USA, 81, 5699-703. https://doi.org/10.1073/pnas.81.18.5699
  28. Yanaihara C, Inoue A, Mochizuki T, et al (1978). Bombesinlike immunoreactivity in mammalian tissues. Biomed Res, 1, 767-74.